These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33468471)

  • 21. Klebsiella pneumoniae carbapenemase (KPC) in urinary infection isolates.
    Bedenić B; Sardelić S; Bogdanić M; Zarfel G; Beader N; Šuto S; Krilanović M; Vraneš J
    Arch Microbiol; 2021 May; 203(4):1825-1831. PubMed ID: 33507339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temocillin and piperacillin/tazobactam resistance by disc diffusion as antimicrobial surrogate markers for the detection of carbapenemase-producing Enterobacteriaceae in geographical areas with a high prevalence of OXA-48 producers.
    Huang TD; Poirel L; Bogaerts P; Berhin C; Nordmann P; Glupczynski Y
    J Antimicrob Chemother; 2014 Feb; 69(2):445-50. PubMed ID: 24055766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repurposing the anti-viral drug zidovudine (AZT) in combination with meropenem as an effective treatment for infections with multi-drug resistant, carbapenemase-producing strains of Klebsiella pneumoniae.
    DeSarno AE; Parcell BJ; Coote PJ
    Pathog Dis; 2020 Dec; 78(9):. PubMed ID: 33053176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.
    Islam K; Sime FB; Wallis SC; Bauer MJ; Forde BM; Harris P; Shirin T; Habib ZH; Flora MS; Roberts JA
    J Antimicrob Chemother; 2022 Aug; 77(9):2448-2455. PubMed ID: 35724128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fosfomycin-meropenem synergistic combination against NDM carbapenemase-producing Klebsiella pneumoniae strains.
    Della Rocca MT; Di Caprio G; Colucci F; Merola F; Panetta V; Cordua E; Greco R
    New Microbiol; 2023 Sep; 46(3):264-270. PubMed ID: 37747471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of polymyxin B combinations against genetically well-characterised Klebsiella pneumoniae producing NDM-1 and OXA-48-like carbapenemases.
    Olsson A; Allander L; Shams A; Al-Farsi H; Lagerbäck P; Tängdén T
    Int J Antimicrob Agents; 2023 Nov; 62(5):106967. PubMed ID: 37716575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and/or NDM-producing
    Erturk Sengel B; Altinkanat Gelmez G; Soyletir G; Korten V
    J Chemother; 2020 Sep; 32(5):237-243. PubMed ID: 32228228
    [No Abstract]   [Full Text] [Related]  

  • 28. Performance Evaluation of MALDI-TOF MS MBT STAR-BL Versus In-House Carba NP Testing for the Rapid Detection of Carbapenemase Activity in
    Akyar I; Kaya Ayas M; Karatuna O
    Microb Drug Resist; 2019 Sep; 25(7):985-990. PubMed ID: 30939067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interactions of Polymyxin B in Combination with Aztreonam, Minocycline, Meropenem, and Rifampin against Escherichia coli Producing NDM and OXA-48-Group Carbapenemases.
    Olsson A; Hong M; Al-Farsi H; Giske CG; Lagerbäck P; Tängdén T
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0106521. PubMed ID: 34516251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicentre investigation of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Bulgarian hospitals - Interregional spread of ST11 NDM-1-producing K. pneumoniae.
    Markovska R; Stoeva T; Boyanova L; Stankova P; Schneider I; Keuleyan E; Mihova K; Murdjeva M; Sredkova M; Lesseva M; Nedelcheva G; Petrova A; Ivanova D; Lazarova G; Kaneva R; Mitov I
    Infect Genet Evol; 2019 Apr; 69():61-67. PubMed ID: 30654179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SHV Hyperproduction as a Mechanism for Piperacillin-Tazobactam Resistance in Extended-Spectrum Cephalosporin-Susceptible
    Han MS; Park KS; Jeon JH; Lee JK; Lee JH; Choi EH; Lee SH
    Microb Drug Resist; 2020 Apr; 26(4):334-340. PubMed ID: 31651221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of in vitro methods for testing tigecycline combinations against carbapenemase-producing Klebsiella pneumoniae isolates.
    Papoutsaki V; Galani I; Papadimitriou E; Karantani I; Karaiskos I; Giamarellou H
    J Glob Antimicrob Resist; 2020 Mar; 20():98-104. PubMed ID: 31398495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales.
    Shi S; Zhang X; Yao Z; Xu M; Zhou B; Liu Q; Zhang Y; Zhou C; Zhou T; Ye J
    J Antimicrob Chemother; 2022 Apr; 77(5):1301-1305. PubMed ID: 35165715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
    Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testing the mutant selection window hypothesis with meropenem: In vitro model study with OXA-48-producing Klebsiella pneumoniae.
    Alieva KN; Golikova MV; Dovzhenko SA; Kobrin MB; Strukova EN; Ageevets VA; Avdeeva AA; Sulian OS; Sidorenko SV; Zinner SH
    PLoS One; 2023; 18(8):e0288660. PubMed ID: 37540701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of specific inhibitors on metallo-β-carbapenemases detected in Escherichia coli and Klebsiella pneumoniae isolates.
    Abbas HA; Kadry AA; Shaker GH; Goda RM
    Microb Pathog; 2019 Jul; 132():266-274. PubMed ID: 31096002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
    Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19).
    Shortridge D; Carvalhaes C; Deshpande L; Castanheira M
    J Antimicrob Chemother; 2021 Sep; 76(10):2600-2605. PubMed ID: 34302173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
    JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.